In addition, methylation at CpG sites #8 to #10 was associated with the category of Ras pathway mutation (Additional file 1: Table S3), being considerably higher in JMML cases with PTPN11 mutation or neurofibromatosis type 1 (NF1) than in JMML with KRAS, NRAS, or CBL mutation. Here, KRAS is linked to juvenile myelomonocytic leukemia.